Big news for blood cancer treatment: Johnson & Johnson’s Tecvayli just crushed it in a major study, showing it can slow down multiple myeloma and help patients live longer—even when other meds stop working. The numbers are wild: 71% less risk of cancer getting worse and 40% less risk of death compared to standard treatments. If you know anyone touched by this disease, this could be a total game-changer. #Health #BodyHealth #CancerResearch